6533b856fe1ef96bd12b1ee0

RESEARCH PRODUCT

Cutaneous complications of Anderson-Fabry disease.

Maria Rita BongiornoDaniele RizzoGiuseppe Pistone

subject

MalePathologymedicine.medical_specialtySkin NeoplasmsGlobotriaosylceramideDiseaseDiagnosis Differentialchemistry.chemical_compoundDrug DiscoverymedicineHumansAge FactorEnzyme Replacement TherapySkin NeoplasmAnhidrosisSkinPharmacologySex CharacteristicsVascular diseasebusiness.industryAge FactorsEnzyme replacement therapySex Characteristicmedicine.diseaseFabry diseaseAngiokeratomaLymphedemachemistryalpha-GalactosidaseFabry DiseaseFemalemedicine.symptombusinessHumanAngiokeratoma

description

Anderson-Fabry disease is an X-linked lysosomal storage disorder caused by a defect in the -galactosidase A gene, which leads to the deficiency of the hydrolytic enzyme -galactosidase A. The consequent inability to catabolize glycosphingolipids causes progressive accumulation of globotriaosylceramide in the vascular endothelium throughout the body. Fatalities in the classical phenotype may usually occur as a consequence of cerebral, cardiac or renal disease. Dermatological manifestations are a relevant feature of Fabry disease and include angiokeratomas, telangiectasiae, lymphedema, anhidrosis or hypohidrosis and pseudo-acromegalic facial appearance. The actual causal treatment for Fabry disease is the enzyme replacement therapy. Dermatologists have a key role, since cutaneous manifestations may lead to the diagnosis. This may help an early therapeutic intervention, reducing both morbidity and mortality.

10.2174/13816128113199990359https://pubmed.ncbi.nlm.nih.gov/23448454